Cargando…
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice
Rationale: Sclerostin inhibition demonstrated bone anabolic potential in osteogenesis imperfecta (OI) mice, whereas humanized therapeutic sclerostin antibody romosozumab for postmenopausal osteoporosis imposed clinically severe cardiac ischemic events. Therefore, it is desirable to develop the next...
Autores principales: | Wang, Luyao, Yu, Yuanyuan, Ni, Shuaijian, Li, Dijie, Liu, Jin, Xie, Duoli, Chu, Hang Yin, Ren, Qing, Zhong, Chuanxin, Zhang, Ning, Li, Nanxi, Sun, Meiheng, Zhang, Zong-Kang, Zhuo, Zhenjian, Zhang, Huarui, Zhang, Shu, Li, Mei, Xia, Weibo, Zhang, Zhenlin, Chen, Lin, Shang, Peng, Pan, Xiaohua, Lu, Aiping, Zhang, Bao-Ting, Zhang, Ge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373813/ https://www.ncbi.nlm.nih.gov/pubmed/35966595 http://dx.doi.org/10.7150/thno.63177 |
Ejemplares similares
-
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
por: Yu, Yuanyuan, et al.
Publicado: (2022) -
Drug discovery of sclerostin inhibitors
por: Yu, Sifan, et al.
Publicado: (2022) -
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research
por: Sun, Meiheng, et al.
Publicado: (2021) -
Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
por: Cardinal, Mickaël, et al.
Publicado: (2021) -
Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research
por: Sun, Meiheng, et al.
Publicado: (2020)